RxDoctor Payments DataLook up a doctor →

David Hirsch

Pain Medicine · Bossier City, LANPI 1841580776

Payments from drug & device makers

$5,175in general payments, 2019–2025

Across 349 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$994
  • Boston Scientific$960
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$523
  • Pfizer$429
  • Amgen$389
  • Inari Medical, Inc.$215
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,175 in reported general payments places this provider in the 60th percentile of 97 pain medicine providers in Louisiana.

See all pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$732,403
Medicare patients
1,057
Services billed
25,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl299$219,833
Buprenorphine718$136,653
RelistorMethylnaltrexone Bromide27$81,625
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,350$66,964
Xtampza ErOxycodone Myristate80$55,305
Tramadol Hcl ErTramadol Hcl779$46,905
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,694$46,619
Nurtec OdtRimegepant Sulfate27$31,667
MovantikNaloxegol Oxalate53$23,766
NucyntaTapentadol Hcl13$17,695
OxycontinOxycodone Hcl22$17,091
UbrelvyUbrogepant11$13,617
Gabapentin1,288$13,383
Oxycodone Hcl434$11,052
Pregabalin861$10,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$171$292,832392 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$523$81,62527 claims
PfizerNurtec Odt$429$31,66727 claims
Redhill Biopharma Inc.Movantik$20$23,76653 claims
AbbVieUbrelvy, Linzess$994$22,04527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 97 pain medicine providers in Louisiana.

Other pain medicine in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →